You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR COGENTIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cogentin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018200 ↗ Effect of Antidepressants on Back Pain Completed US Department of Veterans Affairs Phase 2 1999-04-01 The purpose of this study is to determine whether different types of antidepressant medicines relieve back pain that has lasted at least six months on a daily basis. Study participants will be assigned to treatment with either a antidepressant acting on the serotonin system in the brain (fluoxetine), one acting on the noradrenaline system (desipramine, or to a control medication not expected to relieve pain (benztropine). Each participant will be seen at least nine times during their 12 weeks on medication. This is a phase 2/3, outpatient study.
NCT00018200 ↗ Effect of Antidepressants on Back Pain Completed VA Office of Research and Development Phase 2 1999-04-01 The purpose of this study is to determine whether different types of antidepressant medicines relieve back pain that has lasted at least six months on a daily basis. Study participants will be assigned to treatment with either a antidepressant acting on the serotonin system in the brain (fluoxetine), one acting on the noradrenaline system (desipramine, or to a control medication not expected to relieve pain (benztropine). Each participant will be seen at least nine times during their 12 weeks on medication. This is a phase 2/3, outpatient study.
NCT00457366 ↗ A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Completed AstraZeneca Phase 4 2006-05-01 In the Psychiatric Emergency Room, agitated patients are treated routinely with an I.M. Haloperidol "cocktail" (Haloperidol 5 mg, Lorazepam 2 mg, Cogentin 2 mg), which has proved to be an effective treatment. However, since it is an intramuscular injection, it is more complicated and perhaps less acceptable to patients as well as more likely to cause EPS (extrapyramidal symptoms). Of late in our emergency room, we started using high dose Quetiapine 300 mg PO to replace the "cocktail" for treating agitation. It has shown promising results.
NCT00457366 ↗ A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Completed University of Southern California Phase 4 2006-05-01 In the Psychiatric Emergency Room, agitated patients are treated routinely with an I.M. Haloperidol "cocktail" (Haloperidol 5 mg, Lorazepam 2 mg, Cogentin 2 mg), which has proved to be an effective treatment. However, since it is an intramuscular injection, it is more complicated and perhaps less acceptable to patients as well as more likely to cause EPS (extrapyramidal symptoms). Of late in our emergency room, we started using high dose Quetiapine 300 mg PO to replace the "cocktail" for treating agitation. It has shown promising results.
NCT00802100 ↗ Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 2008-12-01 This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
NCT00964886 ↗ Efficacy of Antidepressants in Chronic Back Pain Completed University of California, San Diego Phase 2 2010-01-01 This 12 week placebo controlled clinical trial tests the individual and combined effects of an antidepressant medication and cognitive behavioral therapy for chronic back pain.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cogentin

Condition Name

Condition Name for Cogentin
Intervention Trials
Back Pain 2
Breast Cancer 1
Cardiac Toxicities 1
Cognitive Impairment 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cogentin
Intervention Trials
Back Pain 2
Peripheral Nervous System Diseases 1
Cognitive Dysfunction 1
Cardiotoxicity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cogentin

Trials by Country

Trials by Country for Cogentin
Location Trials
United States 14
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cogentin
Location Trials
California 4
Georgia 1
Florida 1
Connecticut 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cogentin

Clinical Trial Phase

Clinical Trial Phase for Cogentin
Clinical Trial Phase Trials
Phase 4 2
Phase 2/Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cogentin
Clinical Trial Phase Trials
Completed 4
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cogentin

Sponsor Name

Sponsor Name for Cogentin
Sponsor Trials
VA Office of Research and Development 2
US Department of Veterans Affairs 1
AstraZeneca 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cogentin
Sponsor Trials
U.S. Fed 3
Other 3
Industry 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.